Tag: BGMD

  • Healthcare Gainers: BG Medicine (NASDAQ:BGMD), Novavax (NASDAQ:NVAX), OXiGENE (NASDAQ:OXGN), NPS Pharmaceuticals (NASDAQ:NPSP)

    BG Medicine, Inc. (NASDAQ:BGMD) ripping after it reported the publication of results, in the American Heart Journal, of an analysis of aggregated data from three large, multicentre clinical research trials in the United States and Europe. BG Medicine, Inc. (NASDAQ:BGMD) shares after opening at $1.89 moved to $2.42 on last trade day and at the end of the day closed at $2.08. Company price to sales ratio in past twelve months was calculated as 14.52 and price to cash ratio as 5.14. BG Medicine, Inc. (NASDAQ:BGMD) showed a positive weekly performance of 12.43%.

    Novavax (NASDAQ:NVAX) Director Richard Douglas acquired 50,000 shares of Novavax stock in a transaction that occurred on Tuesday, March 25th. The stock was purchased at an average price of $4.33 per share, with a total value of $216,500.00. Following the completion of the acquisition, the director now directly owns 250,000 shares of the company’s stock, valued at approximately $1,082,500. Novavax, Inc. (NASDAQ:NVAX) shares advanced 8.47% in last trading session and ended the day on $4.48. NVAX return on equity ratio is recorded as -41.40% and its return on assets is -34.10%. Novavax, Inc. (NASDAQ:NVAX) yearly performance is 107.41%.

    OXiGENE, Inc. (NASDAQ:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the year ended December 31, 2013. OXiGENE Inc. (NASDAQ:OXGN) shares moved up 8.07% in last trading session and was closed at $3.75, while trading in range of $3.35 – $3.80. OXiGENE Inc. (NASDAQ:OXGN) year to date (YTD) performance is 48.81%.

    Research analysts at Goldman Sachs assumed coverage on shares of NPS Pharmaceuticals (NASDAQ:NPSP) in a report released on Monday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) weekly performance is -13.32%. On last trading day company shares ended up $29.22. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) distance from 50-day simple moving average (SMA50) is -16.89%. Analysts mean target price for the company is $43.50.